Gamida Cell Added to NASDAQ Biotechnology Index

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

The NASDAQ Biotechnology Index forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF (Nasdaq: IBB). More information about the Index can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005103/en/

For investors: Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 1-212-362-1200

For media: Matthew Corcoran Ten Bridge Communications mcorcoran@tenbridgecommunications.com 1-617-866-7350

Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Aug 2024 to Sep 2024